• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

mTOR 抑制剂宫内给药治疗胎儿结节性硬化症相关横纹肌瘤的 3 年随访结果。

Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.

机构信息

Department of Medical Genetics, Medical School and Clinical Centre, University of Pécs, H-7624 Pécs, Hungary.

Bethesda Children's Hospital, H-1146 Budapest, Hungary.

出版信息

Int J Mol Sci. 2023 Aug 17;24(16):12886. doi: 10.3390/ijms241612886.

DOI:10.3390/ijms241612886
PMID:37629066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10454323/
Abstract

Tuberous sclerosis complex (TSC) is a multisystem disorder characterized by seizures, neuropsychiatric disorders, and tumors of the heart, brain, skin, lungs, and kidneys. We present a three-year follow-up of a patient with TSC-associated rhabdomyoma detected in utero. Genetic examination of the fetus and the parents revealed a de novo variant in the gene (c.3037delG, p.Asp1013IlefsTer3). Oral everolimus was initiated in the pregnant mother to regress the fetal tumor, which was successful. To the best of our knowledge, there is very little information regarding the use of everolimus therapy during pregnancy. West-syndrome was diagnosed when the proband was four months old. The symptoms were well-manageable, however temporarily. Therapy-resistant focal seizures were frequent. The patient had good vitals and was under regular cardiological control, showed a balanced circulation, and did not require any medication. Subependymal giant cell astrocytoma (SEGA) identified by regular neuroimaging examinations remained unchanged, which may be a consequence of early intrauterine treatment. Early detection of the pathogenic variant, followed by in utero administration of everolimus and early vigabatrin therapy, allowed the detection of a milder developmental delay of the proband. Our study emphasizes how early genetic testing and management of epilepsy are pivotal for proper neurodevelopmental impacts and therapeutic strategies.

摘要

结节性硬化症复合征(TSC)是一种多系统疾病,其特征为癫痫发作、神经精神障碍以及心脏、脑、皮肤、肺和肾脏的肿瘤。我们报告了一例在宫内发现的与 TSC 相关的横纹肌瘤患者的三年随访结果。对胎儿及其父母进行基因检查发现了一个新出现的 基因变异(c.3037delG,p.Asp1013IlefsTer3)。为了使胎儿肿瘤消退,给孕妇口服依维莫司,但我们所知,在怀孕期间使用依维莫司治疗的信息非常有限。当患儿四个月大时,被诊断为 West 综合征。症状虽然可以得到暂时控制,但仍很严重。频繁出现治疗抵抗性局灶性癫痫发作。患儿生命体征良好,定期接受心内科检查,循环稳定,无需用药。定期神经影像学检查发现的室管膜下巨细胞星形细胞瘤(SEGA)保持不变,这可能是宫内治疗的结果。早期发现致病性 变异,并在宫内给予依维莫司和早期加巴喷丁治疗,使得患儿的发育迟缓程度较轻。我们的研究强调了早期进行基因检测和癫痫管理对于适当的神经发育影响和治疗策略的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/c94fde7fd313/ijms-24-12886-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/fb93891a6d58/ijms-24-12886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/f5d4c4e0b5a8/ijms-24-12886-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/7c82cd03eabb/ijms-24-12886-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/c94fde7fd313/ijms-24-12886-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/fb93891a6d58/ijms-24-12886-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/f5d4c4e0b5a8/ijms-24-12886-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/7c82cd03eabb/ijms-24-12886-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7806/10454323/c94fde7fd313/ijms-24-12886-g004.jpg

相似文献

1
Three-Year Follow-Up after Intrauterine mTOR Inhibitor Administration for Fetus with TSC-Associated Rhabdomyoma.mTOR 抑制剂宫内给药治疗胎儿结节性硬化症相关横纹肌瘤的 3 年随访结果。
Int J Mol Sci. 2023 Aug 17;24(16):12886. doi: 10.3390/ijms241612886.
2
Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report.依维莫司作为一种可能的产前治疗方法,用于宫内诊断的结节性硬化症患者的室管膜下病变:病例报告。
Childs Nerv Syst. 2021 Dec;37(12):3897-3899. doi: 10.1007/s00381-021-05218-4. Epub 2021 May 18.
3
Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.2 岁以下结节性硬化症患者使用 mTOR 抑制剂治疗的安全性和有效性 - 一项多中心回顾性研究。
Orphanet J Rare Dis. 2019 May 3;14(1):96. doi: 10.1186/s13023-019-1077-6.
4
Use of mTOR inhibitor everolimus in three neonates for treatment of tumors associated with tuberous sclerosis complex.在三名新生儿中使用mTOR抑制剂依维莫司治疗与结节性硬化症相关的肿瘤。
Pediatr Neurol. 2015 Apr;52(4):450-3. doi: 10.1016/j.pediatrneurol.2015.01.004. Epub 2015 Jan 14.
5
Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study.结节性硬化症的发病率和首次诊断年龄:来自一项全国性前瞻性监测研究的新数据和新趋势。
Orphanet J Rare Dis. 2018 Jul 17;13(1):117. doi: 10.1186/s13023-018-0870-y.
6
Prenatal diagnosis of giant cardiac rhabdomyoma in tuberous sclerosis complex: a new therapeutic option with everolimus.结节性硬化症合并巨大心脏横纹肌瘤的产前诊断:依维莫司的一种新治疗选择。
Ultrasound Obstet Gynecol. 2015 May;45(5):618-21. doi: 10.1002/uog.13434.
7
Regression of a cardiac rhabdomyoma in a patient receiving everolimus.患者接受依维莫司治疗后心脏横纹肌瘤消退。
Pediatrics. 2011 May;127(5):e1335-7. doi: 10.1542/peds.2010-2910. Epub 2011 Apr 4.
8
Regression of symptomatic multiple cardiac rhabdomyomas associated with tuberous sclerosis complex in a newborn receiving everolimus.接受依维莫司治疗的新生儿中,与结节性硬化症相关的有症状多发性心脏横纹肌瘤的消退。
J Trop Pediatr. 2015 Feb;61(1):74-7. doi: 10.1093/tropej/fmu056. Epub 2014 Oct 24.
9
Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.依维莫司改善了一名携带新型TSC2突变的结节性硬化症患者的神经精神症状。
Mol Brain. 2016 May 23;9(1):56. doi: 10.1186/s13041-016-0222-6.
10
Long-term effect of everolimus on epilepsy and growth in children under 3 years of age treated for subependymal giant cell astrocytoma associated with tuberous sclerosis complex.特发性婴儿痉挛症与结节性硬化症相关室管膜下巨细胞星形细胞瘤患儿接受依维莫司治疗的长期疗效及生长情况。
Eur J Paediatr Neurol. 2013 Sep;17(5):479-85. doi: 10.1016/j.ejpn.2013.03.002. Epub 2013 Apr 6.

引用本文的文献

1
Drug review: mTOR-inhibitor therapy in fetal cardiac rhabdomyoma-a tightrope walk.药物综述:胎儿心脏横纹肌瘤的mTOR抑制剂治疗——如履薄冰。
Front Pediatr. 2025 Aug 26;13:1649341. doi: 10.3389/fped.2025.1649341. eCollection 2025.
2
Genetic screening of tuberous sclerosis complex in Sicily with a focus on neurological manifestations.西西里岛结节性硬化症的基因筛查:聚焦神经学表现
Sci Rep. 2025 Jun 27;15(1):20347. doi: 10.1038/s41598-025-04718-6.
3
Transplacental sirolimus: a new treatment strategy for life-threatening fetal cardiac rhabdomyomas-a case report.

本文引用的文献

1
A case of massive fetal cardiac rhabdomyoma: ultrasound features and management.巨大胎儿心脏横纹肌瘤 1 例:超声特征与处理。
J Matern Fetal Neonatal Med. 2023 Dec;36(1):2197099. doi: 10.1080/14767058.2023.2197099.
2
Case report: Accelerated regression of giant cardiac rhabdomyomas in neonates with low dose everolimus.病例报告:低剂量依维莫司治疗新生儿巨大心脏横纹肌瘤的加速消退
Front Pediatr. 2023 Feb 15;11:1109646. doi: 10.3389/fped.2023.1109646. eCollection 2023.
3
Epileptogenesis in tuberous sclerosis complex-related developmental and epileptic encephalopathy.
经胎盘西罗莫司:一种治疗危及生命的胎儿心脏横纹肌瘤的新策略——病例报告
Orphanet J Rare Dis. 2025 Jun 9;20(1):291. doi: 10.1186/s13023-025-03780-7.
4
Mechanistic strategies for secondary prevention of developmental and epileptic encephalopathy in children with tuberous sclerosis complex.结节性硬化症患儿发育性和癫痫性脑病二级预防的机制策略
EBioMedicine. 2025 Jun;116:105740. doi: 10.1016/j.ebiom.2025.105740. Epub 2025 May 13.
5
Three-Dimensional Ultrasound for Physical and Virtual Fetal Heart Models: Current Status and Future Perspectives.用于物理和虚拟胎儿心脏模型的三维超声:现状与未来展望
J Clin Med. 2024 Dec 13;13(24):7605. doi: 10.3390/jcm13247605.
结节性硬化症相关发育性和癫痫性脑病中的癫痫发生机制。
Brain. 2023 Jul 3;146(7):2694-2710. doi: 10.1093/brain/awad048.
4
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).美国医学遗传学与基因组学学会(ACMG)关于临床外显子组和基因组测序中次要发现报告的ACMG SF v3.1清单:一项政策声明
Genet Med. 2022 Jul;24(7):1407-1414. doi: 10.1016/j.gim.2022.04.006. Epub 2022 Jun 17.
5
The non-essential TSC complex component TBC1D7 restricts tissue mTORC1 signaling and brain and neuron growth.非必需的 TSC 复合物成分 TBC1D7 限制组织 mTORC1 信号转导以及脑和神经元生长。
Cell Rep. 2022 May 17;39(7):110824. doi: 10.1016/j.celrep.2022.110824.
6
Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations.更新后的国际结节性硬化症复合体诊断标准及监测与管理建议。
Pediatr Neurol. 2021 Oct;123:50-66. doi: 10.1016/j.pediatrneurol.2021.07.011. Epub 2021 Jul 24.
7
Everolimus as a possible prenatal treatment of in utero diagnosed subependymal lesions in tuberous sclerosis complex: a case report.依维莫司作为一种可能的产前治疗方法,用于宫内诊断的结节性硬化症患者的室管膜下病变:病例报告。
Childs Nerv Syst. 2021 Dec;37(12):3897-3899. doi: 10.1007/s00381-021-05218-4. Epub 2021 May 18.
8
Stepwise ABC system for classification of any type of genetic variant.逐步 ABC 系统,用于分类任何类型的遗传变异。
Eur J Hum Genet. 2022 Feb;30(2):150-159. doi: 10.1038/s41431-021-00903-z. Epub 2021 May 13.
9
Everolimus inhibits PI3K/Akt/mTOR and NF-kB/IL-6 signaling and protects seizure-induced brain injury in rats.依维莫司抑制 PI3K/Akt/mTOR 和 NF-κB/IL-6 信号通路,保护大鼠癫痫诱导的脑损伤。
J Chem Neuroanat. 2021 Jul;114:101960. doi: 10.1016/j.jchemneu.2021.101960. Epub 2021 Apr 26.
10
Fetal cardiac tumors: prenatal diagnosis, management and prognosis in 18 cases.胎儿心脏肿瘤:18例的产前诊断、处理及预后
J Turk Ger Gynecol Assoc. 2020 Dec 4;21(4):255-259. doi: 10.4274/jtgga.galenos.2020.2019.0180.